AZD2284

AZD2284 is an investigational radioligand therapy currently in Phase I clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is being developed as a targeted therapy, where the molecule is conjugated with Actinium-225, a radioactive isotope. The drug is designed to deliver targeted radiation to cancer cells expressing specific biomarkers such as Prostate-Specific Membrane Antigen (PSMA) and Six-Transmembrane Epithelial Antigen of Prostate 2 (STEAP2), which are prevalent in advanced prostate cancers. The mechanism involves using an antibody or ligand that binds these antigens on tumor cells, allowing precise delivery of alpha-emitting radiation from Actinium-225 to induce cytotoxicity and cell death in malignant tissue while sparing normal cells. This approach aims to improve efficacy and reduce off-target toxicity compared to conventional therapies[5][7].

Other names

225Ac-AZD2284